| P50 | author | Timothy Synold | Q78536675 |
| P2093 | author name string | Paul Frankel | |
| | Yun Yen | |
| | Robert Chen | |
| | Kenneth K Chan | |
| | Edward M Newman | |
| | Leslie Popplewell | |
| | Zhiliang Xie | |
| | Joseph M Tuscano | |
| | Omar Aljitawi | |
| | Mark H Kirschbaum | |
| P2860 | cites work | Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia | Q34358512 |
| | Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study | Q34611822 |
| | Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia | Q34983843 |
| | An overview of the clinical experience with hydroxyurea | Q36370103 |
| | Isolation and characterization of expressible cDNA clones encoding the M1 and M2 subunits of mouse ribonucleotide reductase | Q36426076 |
| | Ribonucleotide reductase inhibitors and future drug design | Q36569850 |
| | The RR1 gene of herpes simplex virus type 1 is uniquely trans activated by ICP0 during infection | Q36653717 |
| | Structure and promoter characterization of the gene encoding the large subunit (R1 protein) of mouse ribonucleotide reductase | Q36701414 |
| | A phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer: a study of the PMH phase II consortium | Q37327229 |
| | Enhanced malignant transformation induced by expression of a distinct protein domain of ribonucleotide reductase large subunit from herpes simplex virus type 2. | Q37595924 |
| | Ribonucleotide reductase inhibitors as anticancer and antiviral agents | Q39694575 |
| | Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia | Q40543180 |
| | The mammalian ribonucleotide reductase R2 component cooperates with a variety of oncogenes in mechanisms of cellular transformation | Q41048019 |
| | Ribonucleotide reductase R2 gene expression and changes in drug sensitivity and genome stability | Q41081965 |
| | Hydroxyurea as a radiation sensitizer in women with carcinoma of the uterine cervix | Q41324825 |
| | Characterization of a hydroxyurea-resistant human KB cell line with supersensitivity to 6-thioguanine. | Q41455136 |
| | Analysis of a herpes simplex virus 2 fragment from the open reading frame of the large subunit of ribonucleotide reductase with transcriptional regulatory activity | Q41570814 |
| | Mammalian drug resistant mutants with multiple gene amplifications: genes encoding the M1 component of ribonucleotide reductase, the M2 component of ribonucleotide reductase, ornithine decarboxylase, p5-8, the H-subunit of ferritin and the L-subunit | Q41717819 |
| | S-Phase-specific expression of mammalian ribonucleotide reductase R1 and R2 subunit mRNAs | Q41731157 |
| | Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia | Q44551806 |
| | A truncated protein kinase domain of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10) expressed in Escherichia coli | Q45366415 |
| | Epitope mapping identifies an exposed loop between the unique amino- and conserved carboxy-domains of the large subunit of herpes simplex virus type 1 ribonucleotide reductase | Q45786707 |
| | A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer. | Q45906799 |
| | Analysis of ribonucleotide reductase M2 mRNA levels in patient samples after GTI-2040 antisense drug treatment | Q47598730 |
| | GTI-2040, an antisense agent targeting the small subunit component (R2) of human ribonucleotide reductase, shows potent antitumor activity against a variety of tumors. | Q48292444 |
| | Triapine (3-aminopyridine-2-carboxaldehyde- thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity. | Q54061261 |
| | Molecular mechanisms of drug resistance involving ribonucleotide reductase: hydroxyurea resistance in a series of clonally related mouse cell lines selected in the presence of increasing drug concentrations. | Q54275555 |
| | Molecular and cellular characterization of drug resistant hamster cell lines with alterations in ribonucleotide reductase. | Q54373240 |
| | Subunit M2 of mammalian ribonucleotide reductase. Characterization of a homogeneous protein isolated from M2-overproducing mouse cells. | Q54453155 |
| | A Specific Picomolar Hybridization-Based ELISA Assay for the Determination of Phosphorothioate Oligonucleotides in Plasma and Cellular Matrices | Q60325954 |
| | Substrate specificity of human ribonucleotide reductase from Molt-4F cells | Q66957034 |
| | Effect of hydroxyurea on ribonucleotide reductase | Q68585131 |
| | Hydroxyurea in the treatment of neoplasms of the head and neck | Q69593042 |
| | Cell cycle-dependent expression of mammalian ribonucleotide reductase. Differential regulation of the two subunits | Q69900353 |
| | Regulation of ribonucleotide reductase activity in mammalian cells | Q70284517 |
| | Cellular pharmacodynamics and plasma pharmacokinetics of parenterally infused hydroxyurea during a phase I clinical trial in chronic myelogenous leukemia | Q74784085 |
| | A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma | Q80478185 |
| | A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors | Q81638797 |
| | Preclinical toxicity and toxicokinetics of GTI-2040, a phosphorothioate oligonucleotide targeting ribonucleotide reductase R2 | Q85118698 |
| P433 | issue | 10 | |
| P921 | main subject | California | Q99 |
| | pharmacodynamics | Q725307 |
| P304 | page(s) | 2307-2314 | |
| P577 | publication date | 2016-02-19 | |
| P1433 | published in | Leukemia & Lymphoma | Q6534493 |
| P1476 | title | A phase I pharmacodynamic study of GTI-2040, an antisense oligonucleotide against ribonuclotide reductase, in acute leukemias: a California Cancer Consortium study | |
| P478 | volume | 57 | |